Open Access

REVIEW

Raffaele Carrano^1,#, Carlotta Zucca^1,#, Nicla Cristina¹, Martina Grande¹, Eleonora Leti Maggio¹, Riccardo Bei², Antonio Infante², Chiara Focaccetti¹, Valeria Lucarini³, Loredana Cifaldi¹, Laura Masuelli⁴, Luciano Mutti⁵, Camilla Palumbo¹, Monica Benvenuto¹, Roberto Bei^1,*
Oncology Research, Vol.33, No.9, pp. 2181-2204, 2025, DOI:10.32604/or.2025.066708 - 28 August 2025
（This article belongs to the Special Issue: Immunotherapy and Chemotherapy: Synergies and Challenges in the Evolving Landscape of Cancer Treatment)
Abstract Mesothelioma is a rare and aggressive cancer with a poor prognosis and limited therapeutic options. Despite recent advances, conventional treatment approaches remain largely ineffective due to late diagnosis, chemoresistance and immunosuppressive tumor microenvironment. This review reports the latest studies on combination therapies for mesothelioma, focusing on the potential of integrating chemotherapeutic agents, molecularly targeted agents, vaccines and natural bioactive compounds such as polyphenols. Clinical and preclinical studies demonstrate that integrating immune-modulating drugs or molecular inhibitors with chemotherapy can improve survival and reduce tumor progression in mesothelioma models and patients. Vaccine-based strategies show potential for inducing More >

Graphic Abstract

View

1672

Download

1055

Open Access

REVIEW

Akari Fukumoto, Satoru Matsuda^*
Oncology Research, Vol.33, No.9, pp. 2205-2219, 2025, DOI:10.32604/or.2025.062810 - 28 August 2025
Abstract The non-coding RNAs (ncRNAs) are a family of single-stranded RNAs that have become recognized as crucial gene expression regulators in normal and cancer cell biology. The gut microbiota, which consists of several different bacteria, can actively contribute to the regulation of host metabolism, immunity, and inflammation. Roles of ncRNAs and gut microbiota could significantly interact with each other to regulate the growth of various types of cancer. In particular, a causal relationship among ncRNAs, gut microbiota, and immune cells has been shown for their potential importance in the development of breast cancer. Alteration of ncRNA More >

View

1451

Download

1006

Open Access

REVIEW

Yuriy Mayasin¹, Maria Osinnikova¹, Daria Osadchaya¹, Victoria Dmitrienko¹, Anna Gorodilova¹, Chulpan Kharisova¹, Kristina Kitaeva¹, Ivan Filin¹, Valeria Solovyeva¹, Albert Rizvanov^1,2,*
Oncology Research, Vol.33, No.9, pp. 2221-2242, 2025, DOI:10.32604/or.2025.064677 - 28 August 2025
Abstract Melanoma is a malignant neoplasm with a high propensity to metastasize, arising from melanocytes and contributing significantly to global morbidity and mortality. Despite the demonstrated efficacy of many immunotherapy approaches, these methods rely on direct destruction of tumor cells with minimal impact on the aggregate of nearby non-tumor cells, the extracellular matrix, and blood vessels that form the tumor microenvironment (TME). The TME is known to be heterogeneous and dynamic, exerting both antitumor and pro-tumor effects depending on the specific features and stage of carcinogenesis. TME has been shown in several studies to promote… More >

View

2197

Download

1244

Open Access

REVIEW

David A de la Garza-Kalife¹, Verónica L Loaiza-Gutiérrez¹, Esther Alhelí Hernández-Tobías², Carlos A González-Villarreal³, Jose Francisco Islas¹, Michelle G Santoyo-Suárez¹, Elsa N Garza-Treviño^1,*, Paulina Delgado-Gonzalez^1,*
Oncology Research, Vol.33, No.9, pp. 2243-2262, 2025, DOI:10.32604/or.2025.065222 - 28 August 2025
（This article belongs to the Special Issue: Drug Targets in Oncology: Mechanisms, Challenges, and Innovations)
Abstract Emerging evidence highlights the potential of bioactive compounds, particularly polyphenols, as adjunctive therapeutic agents in the treatment of pancreatic cancer (PC), one of the most aggressive malignancies. This review focuses on epigallocatechin gallate (EGCG) and resveratrol due to their extensively documented anticancer activity, favorable safety profiles, and their unique ability to modulate multiple signaling pathways relevant to pancreatic tumorigenesis. Among polyphenols, these two have shown superior anti-cancer activity, epigenetic regulatory effects, and synergy with standard chemotherapies in preclinical pancreatic cancer models. Resveratrol exhibits anti-proliferative effects by modulating key signaling pathways, including phosphatidylinositol 3 kinase (PI3K)/protein… More >

Graphic Abstract

View

2174

Download

1202

Open Access

REVIEW

Jiao Li^1,2, Nurhayu Ab Rahman^1,3, Suharni Mohamad¹, Guang Yang⁴, Caixia Zhao^2,*
Oncology Research, Vol.33, No.9, pp. 2263-2278, 2025, DOI:10.32604/or.2025.065911 - 28 August 2025
（This article belongs to the Special Issue: Advances in Cancer Immunotherapy)
Abstract Objectives: Checkpoint inhibitors have significantly improved outcomes in a number of malignancies. To determine the most effective course of treatment for head and neck squamous cell carcinoma (HNSCC), this systematic review evaluated the efficacy of several therapeutic approaches based on immune checkpoint inhibitors (ICIs). Methods: A comprehensive evaluation of the literature was conducted, looking at randomized controlled trials (RCTs) that were published in Embase, PubMed, and the Cochrane Central Register of Controlled Trials since database establishment. The risk of bias of the enrolled studies was analyzed using The Review Manager (RevMan) 5.4. Using network meta-analyses… More >

View

1814

Download

1173

Open Access

REVIEW

Prin Sungwan¹, Jutatip Panaampon^1,2, Ratchaneewan Sumankan^1,3, Genki Aoki¹, Seiji Okada^1,*
Oncology Research, Vol.33, No.9, pp. 2279-2307, 2025, DOI:10.32604/or.2025.065319 - 28 August 2025
Abstract Cholangiocarcinoma (CCA) is a fatal bile duct malignancy. CCA is intrinsically resistant to standard chemotherapy, responds poorly to it, and has a poor prognosis. Effective treatments for cholangiocarcinoma remain elusive, and a breakthrough in CCA treatment is still awaited. The human epidermal growth factor receptor 2 (HER2) plays an oncogenic role by promoting an aggressive cancer phenotype through multiple pathways. While HER2 has shown increasing potential as an effective target for breast and gastric cancers over the last decade, this has not been the case for CCA. This review explores the possibility of targeting HER2 More >

Graphic Abstract

View

3415

Download

1535

Open Access

REVIEW

Jiahao Xue^1,#, Jingchang Zhang^2,#, Gang Chen³, Liucui Chen^4,*, Xinjun Lu^1,*
Oncology Research, Vol.33, No.9, pp. 2309-2329, 2025, DOI:10.32604/or.2025.063719 - 28 August 2025
（This article belongs to the Special Issue: Advances in Cancer Immunotherapy)
Abstract Hepatocellular carcinoma (HCC) is a highly aggressive malignancy, largely driven by an immunosuppressive tumor microenvironment (TME) that facilitates tumor growth, immune escape, and resistance to therapy. Although immunotherapy—particularly immune checkpoint inhibitors (ICIs)—has transformed the therapeutic landscape by restoring T cell-mediated anti-tumor responses, their clinical benefit as monotherapy remains suboptimal. This limitation is primarily attributed to immunosuppressive components within the TME, including tumor-associated macrophages, regulatory T cells (Tregs), and myeloid-derived suppressor cells (MDSCs). To address these challenges, combination strategies have been explored, such as dual checkpoint blockade targeting programmed cell death protein 1 (PD-1), programmed death-ligand More >

View

2036

Download

1274

Open Access

ARTICLE

Chi Zhang^1,#, Xi Huang^2,#, Cheng Hu¹, Bowen Tang¹, Jianjie Wu¹, Zhuolun Sun¹, Weian Zhu¹, Xiangfu Zhou¹, Hengjun Xiao^1,*, Hua Wang^1,*
Oncology Research, Vol.33, No.9, pp. 2331-2351, 2025, DOI:10.32604/or.2025.065119 - 28 August 2025
（This article belongs to the Special Issue: Novel Biomarkers and Treatment Strategies in Solid Tumor Diagnosis, Progression, and Prognosis)
Abstract Background: U2AF homology motif kinase 1 (UHMK1) has been associated with RNA processing and protein phosphorylation, thereby influencing tumor progression. The study aimed to explore its regulatory mechanisms and biological functions in human prostate cancer (PCa). Methods: In this study, we systematically evaluated the expression and prognostic significance of UHMK1 in public databases, followed by validation through immunohistochemistry (IHC) in PCa specimens. Both gain-of-function and loss-of-function experiments were conducted to elucidate the role of UHMK1 in vitro and in vivo. Additionally, a series of molecular and biochemical assays were performed to investigate the regulatory mechanisms underlying UHMK1… More >

View

1498

Download

1059

Open Access

ARTICLE

Bi Feng^#, Siqi Yang^#, Zhiqiang He, Yushi Dai, Ruiqi Zou, Yafei Hu, Haijie Hu^*, Fuyu Li^*
Oncology Research, Vol.33, No.9, pp. 2353-2377, 2025, DOI:10.32604/or.2025.061422 - 28 August 2025
（This article belongs to the Special Issue: Novel Biomarkers and Treatment Strategies in Solid Tumor Diagnosis, Progression, and Prognosis)
Abstract Objectives: Hepatocellular carcinoma (HCC) is among the most frequently occurring malignant tumors of the digestive tract and is associated with an increased mortality rate worldwide. This study aimed to develop and validate a prognostic model based on immunogenic cell death (ICD)-related genes to predict patient survival and guide individualized treatment strategies for HCC. Methods: ICD-related genes were identified from the GeneCards database using a relevance score threshold of >10. A combination of least absolute shrinkage and selection operator (LASSO) regression and multivariate Cox analysis was used to screen prognostic genes and construct a risk score… More >

View

1671

Download

1211

Open Access

ARTICLE

Yuhang Jiang^#, Yijun Xu^#, Qi Zhu, Yingxia Wu, Zhe Wang, Shuang He, Shiyong Yu^*, Honggang Xiang^*
Oncology Research, Vol.33, No.9, pp. 2379-2398, 2025, DOI:10.32604/or.2025.063501 - 28 August 2025
（This article belongs to the Special Issue: Advances and Innovations in Colorectal Cancer Research and Treatment)
Abstract Background: Colorectal cancer (CRC) is common and deadly, often leading to metastasis, challenging treatment, and poor outcomes. Understanding its molecular basis is crucial for developing effective therapies. Aims: This study aimed to investigate the role of Myosin Heavy Chain 11 (MYH11) in CRC progression, especially its effects on epithelial-mesenchymal transition (EMT) and cell behavior, and to explore its potential regulation by the EMT transcription factor zinc finger E-box binding homeobox 1 (ZEB1). Methods: Differential expression analysis was performed in the GSE123390 and TCGA-READ datasets, and 317 intersection genes were identified. The hub gene MYH11 was identified… More >

View

1480

Download

1052

Open Access

ARTICLE

Xiaobing Zhou^1,#, Ying Li^2,#, Zizi Jing¹, Wei Yu¹, Jianbin Chen^1,*
Oncology Research, Vol.33, No.9, pp. 2399-2420, 2025, DOI:10.32604/or.2025.063700 - 28 August 2025
Abstract Background: Multiple myeloma (MM) remains a formidable clinical challenge due to its high relapse rate and resistance to existing therapies. Estrogen-related receptor gamma (ERRγ), a nuclear receptor critical for cellular energy metabolism, has been implicated in various cancers. but its role in MM remains unclear. Methods: ERRγ expression was assessed using bioinformatics and RT-qPCR. Functional studies were conducted through siRNA-mediated ERRγ knockdown and treatment with the inverse agonist GSK5182 to examine their effects on MM cell proliferation and apoptosis. Results: ERRγ was significantly upregulated in the bone marrow of MM patients, correlating with advanced clinical stages… More >

Graphic Abstract

View

1804

Download

1049

Open Access

ARTICLE

Lingjuan Linghu^1,#, Hongying Zhou^2,#, Gang Zheng¹, Tao Yi^1,*
Oncology Research, Vol.33, No.9, pp. 2421-2434, 2025, DOI:10.32604/or.2025.063724 - 28 August 2025
（This article belongs to the Special Issue: Advances in Cancer Pharmacology)
Abstract Objectives: Ovarian cancer, a leading cause of gynecological malignancy-related mortality, is characterized by limited therapeutic options and a poor prognosis. Although pyrimethamine has emerged as a promising candidate demonstrating efficacy in treating various tumors, the precise mechanisms of its antitumor effects remain obscure. This study was specifically designed to investigate the mode of action underlying the antitumor effects of pyrimethamine in preclinical settings. Methods: The effects of pyrimethamine on cellular proliferation were meticulously assessed using both the cell counting kit 8 (CCK-8) assay and the colony formation assay, with the effects further confirmed in a… More >

View

1592

Download

1092

Open Access

ARTICLE

Shengmin Li¹, Kejian Shi¹, Ying Wang^2,*, Yi Zhang^1,*
Oncology Research, Vol.33, No.9, pp. 2435-2449, 2025, DOI:10.32604/or.2025.063812 - 28 August 2025
（This article belongs to the Special Issue: Novel Targets and Biomarkers in Solid Tumors)
Abstract Objectives: Lung cancer represents a major global healthcare challenge, characterized by high annual incidence and mortality rates worldwide. Although targeted therapies for lung cancer have advanced, treatment outcomes for advanced-stage patients remain suboptimal. This investigation examines the role of the translocase of the inner mitochondrial membrane (TIMM)8A-TIMM13 complex in lung cancer and evaluates its potential as a novel therapeutic target. Methods: A co-immunoprecipitation (Co-IP) assay was conducted to verify the interaction between TIMM8A and TIMM13. Differential gene expression analysis of TIMM8A or TIMM13 was executed using the TNMplot database, with survival estimates derived from the… More >

View

1479

Download

984

Open Access

ARTICLE

Xi Qin^1,#, Yulan Liu^1,#, Lin Zhu², Yunyan Mo¹, Jing Zhang³, Zhuchun Jiang⁴, Dongning Huang⁵, Xinrong Hu⁶, Jingzhang Li⁷, Quanfang Chen⁸, Feng Xue^1,*
Oncology Research, Vol.33, No.9, pp. 2451-2462, 2025, DOI:10.32604/or.2025.064119 - 28 August 2025
（This article belongs to the Special Issue: Multi-Omics Approaches for Precision Medicine)
Abstract Background: The use of third-generation different tyrosine kinase inhibitors (TKIs) is considered the most effective option for treating advanced non-small cell lung cancer (aNSCLC) with epidermal growth factor receptor (EGFR) mutations. However, there is limited information on the efficacy and safety of aumolertinib in patients remains these cases. Methods: The clinical records of patients receiving aumolertinib as first-line therapy across four hospitals in the Guangxi Zhuang Autonomous Region from April 2020 to December 2021 were retrospectively analyzed, using progression-free survival (PFS) as the primary endpoint and overall survival (OS) representing the secondary endpoint. Adverse events… More >

View

1932

Download

1157

Open Access

ARTICLE

Liangju Peng^1,2, Tingting Cai^1,2, Peihang Xu^1,2, Cong Chen³, Qingzhi Xiang^1,2, Yiping Zhu^1,2, Dingwei Ye^1,2,*, Yijun Shen^1,2,*
Oncology Research, Vol.33, No.9, pp. 2463-2489, 2025, DOI:10.32604/or.2025.064331 - 28 August 2025
Abstract Background: Studies have reported the special value of PANoptosis in cancer, but there is no study on the prognostic and therapeutic effects of PANoptosis in bladder cancer (BLCA). This study aimed to explore the role of PANoptosis in BLCA heterogeneity and its impact on clinical outcomes and immunotherapy response while establishing a robust prognostic model based on PANoptosis-related features. Methods: Gene expression profiles and clinical data were collected from public databases. Spatial heterogeneity of cell death pathways in BLCA was evaluated. Consensus clustering was performed based on identified PANoptosis genes. Cell death pathway scores, molecular, and… More >

View

2018

Download

1296

Open Access

ARTICLE

Xinxin Hu^1,2,#, Yuye Xue^3,#, Fei Fang⁴, Jie Li², Xiaofeng Yuan², Guang Cheng⁵, Hailong Yuan³, Yongqiang Zhang², Yuefei Zhou⁵, Shuangwu Yang⁵, Pengcheng Qiu^2,*, Yunyang Lu², Haifeng Tang^2,*
Oncology Research, Vol.33, No.9, pp. 2491-2506, 2025, DOI:10.32604/or.2025.064454 - 28 August 2025
（This article belongs to the Special Issue: New Insights in Drug Resistance of Cancer Therapy: A New Wine in an Old Bottle)
Abstract Objectives: The Sorbin and SH3 domain containing 1 (SORBS1), a protein linked to insulin signaling CBL interaction, was investigated for its role in pancreatic cancer apoptosis. This study explored polyphyllin H (PPH)’s ability to restore SORBS1-knockdown-mediated repair functions. Methods: PANC-1 cells were divided into Blank, overexpression (OE), and knockdown groups. CCK-8 assays assessed proliferation and drug toxicity. Western blot and flow cytometry analyzed SORBS1 levels and PPH effects. Comet assays quantified DNA damage. Subcutaneous xenograft tumors in nude mice (Blank vs. knockdown) were treated with PPH to evaluate in vivo efficacy. SORBS1-H2AX gene correlation was analyzed… More >

Graphic Abstract

View

1680

Download

1051

Open Access

ARTICLE

Meng Cao, Rundong Zhang, Anlan Hong, Shanyuan Ye, Zequn Qiu, Dongqing Li, Tong Lin^*, Yan Wang^*
Oncology Research, Vol.33, No.9, pp. 2507-2527, 2025, DOI:10.32604/or.2025.064780 - 28 August 2025
（This article belongs to the Special Issue: Signaling Pathway Crosstalk in Malignant Tumors: Molecular Targets and Combinatorial Therapeutics)
Abstract Introduction: Acral melanoma (AM) is the predominant subtype of cutaneous melanoma in Asian populations, characterized by more aggressive clinical features and limited neoadjuvant therapy response. Centrosomal protein 55 kDa (CEP55) has been implicated in the pathogenesis of various malignancies, but its role in AM remains undefined. Methods: CEP55 expression in melanoma tissues and cell lines was analyzed by RT-qPCR, Western blotting, and immunohistochemistry (IHC). Databases (GEPIA, Sangerbox, Kaplan-Meier plotter, and TIMER) were used to analyze the expression of CEP55 and its correlation with clinical data of melanoma patients. Functional assays were conducted in vitro and in vivo.… More >

View

1938

Download

1059

Open Access

ARTICLE

Xizhou Zhang^1,#, Zetao Zhang^1,#, Jianguang Lin², Jiarong Yi³, Xuxiazi Zou³, Jikun Feng³, Guangsheng Huang¹, Bingfeng Chen¹, Junxi Long¹, Fengjia Wu³, Feng Ye^3,*, Haoming Wu^1,*
Oncology Research, Vol.33, No.9, pp. 2529-2547, 2025, DOI:10.32604/or.2025.065029 - 28 August 2025
（This article belongs to the Special Issue: Breast Cancer Biomarkers and Drug Targets Discoveries Towards a More Personalized Treatment Setting)
Abstract Background: Breast cancer remains a leading cause of morbidity and mortality among women worldwide, with significant geographic disparities in its impact. While human epidermal growth factor receptor 2 (HER2)-targeted therapies, such as trastuzumab, have improved outcomes for HER2-positive breast cancer, challenges like therapy resistance persist, highlighting the need for novel treatments. Recent developments in antibody-drug conjugates (ADCs), particularly disitamab vedotin (RC48), show promising efficacy in targeting both HER2-positive and HER2-low expression tumors, warranting further investigation through real-world studies to assess its broader clinical applicability. Method: This retrospective, multicenter observational study evaluated the real-world efficacy and… More >

View

1718

Download

1024

Open Access

ARTICLE

Hailong Li^1,#, Wen Ouyang^2,#, Yiyin Long¹, Yun Peng¹, Ziyi Liu¹, Qi Zhou¹, Rong Xu^1,*, Wei Du^1,*
Oncology Research, Vol.33, No.9, pp. 2549-2571, 2025, DOI:10.32604/or.2025.065050 - 28 August 2025
（This article belongs to the Special Issue: Breast Cancer Biomarkers and Drug Targets Discoveries Towards a More Personalized Treatment Setting)
Abstract Background: The study aimed to explore the clinical value of mitochondrial ribosomal protein L18 (MRPL18) in breast cancer. Methods: Multiple databases were used to validate the expression of MRPL18. The prognostic impact and predictive value of MRPL18 were evaluated by using predictive models. Protein-protein interaction (PPI) networks were constructed by using GeneMANIA. Enrichment analysis is used to explore the signaling pathway regulated by MRPL18. Cell counting kit-8 (CCK-8) assays, colony formation, migration assays, flow cytometry, and xenograft models were employed to evaluate the role of MRPL18 in tumor progression. The immune response of MRPL18 was More >

View

1538

Download

1068

Open Access

ARTICLE

Tatiana M. Astakhova, Nikita S. Karpov, Nataliya O. Dashenkova, Elena V. Alpeeva, Mikhail V. Nesterchuk, Sergey B. Akopov, Arsen S. Mikaelyan, Anfisa S. Ryabchenko, Pavel A. Erokhov, Natalia P. Sharova^*
Oncology Research, Vol.33, No.9, pp. 2573-2595, 2025, DOI:10.32604/or.2025.066611 - 28 August 2025
（This article belongs to the Special Issue: Advances and Innovations in Colorectal Cancer Research and Treatment)
Abstract Objectives: Proteasomes, multi-subunit proteases, are key actors of cellular protein catabolism and a number of regulatory processes. The detection of subtle proteasome functioning in tumors may contribute to our understanding of the mechanisms of cancer development. The current study aimed to identify the role of low molecular mass protein 2 (LMP2), a proteasome immune subunit, in the development of mouse colon 26 (C26) adenocarcinoma. Methods: The functions of the LMP2 subunit in tumor development in Balb/c mice were studied using its irreversible inhibitor KZR-504. LMP2 activity was detected by the hydrolysis of the fluorogenic substrate… More >

View

5558

Download

2215

Open Access

RETRACTION

Oncology Research Editorial Offfce
Oncology Research, Vol.33, No.9, pp. 2597-2597, 2025, DOI:10.32604/or.2025.071883 - 28 August 2025
Abstract This article has no abstract. More >

View

1013

Download

844

Open Access

RETRACTION

Oncology Research Editorial Offfce
Oncology Research, Vol.33, No.9, pp. 2599-2599, 2025, DOI:10.32604/or.2025.071884 - 28 August 2025
Abstract This article has no abstract. More >

View

974

Download

832

Open Access

RETRACTION

Oncology Research Editorial Offfce
Oncology Research, Vol.33, No.9, pp. 2601-2601, 2025, DOI:10.32604/or.2025.071885 - 28 August 2025
Abstract This article has no abstract. More >

View

933

Download

804